Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Interest & Investment Income (2016 - 2026)

Collegium Pharmaceutical has reported Interest & Investment Income over the past 10 years, most recently at $3.6 million for Q4 2025.

  • For Q4 2025, Interest & Investment Income rose 96.74% year-over-year to $3.6 million; the TTM value through Dec 2025 reached $11.3 million, down 19.23%, while the annual FY2025 figure was $11.3 million, 19.23% down from the prior year.
  • Interest & Investment Income for Q4 2025 was $3.6 million at Collegium Pharmaceutical, up from $3.1 million in the prior quarter.
  • Over five years, Interest & Investment Income peaked at $4.5 million in Q3 2023 and troughed at $3000.0 in Q1 2021.
  • A 5-year average of $2.1 million and a median of $2.3 million in 2025 define the central range for Interest & Investment Income.
  • Biggest five-year swings in Interest & Investment Income: plummeted 98.58% in 2021 and later soared 80440.0% in 2023.
  • Year by year, Interest & Investment Income stood at $3000.0 in 2021, then surged by 34133.33% to $1.0 million in 2022, then surged by 318.99% to $4.3 million in 2023, then plummeted by 57.89% to $1.8 million in 2024, then surged by 96.74% to $3.6 million in 2025.
  • Business Quant data shows Interest & Investment Income for COLL at $3.6 million in Q4 2025, $3.1 million in Q3 2025, and $2.4 million in Q2 2025.